new Nasoneb nasal nebuliser reaches the whole sinus cavity
Choosing the right nasal nebuliser system for drug delivery matters.
The NasoNeb® nasal nebuliser delivers a deep, penetrating aerosol to the nasal and paranasal sinus cavities with virtually no incidental pulmonary delivery of drugs and the risk of resultant complications common with small particle nebulizers. 3,4,12,13
NasoNeb nasal nebuliser – about the system …
NasoNeb has changed patient lives by offering real symptom relief for sinus problem sufferers. NasoNeb treatments are fast, effective and more convenient than standard irrigation/ nebuliser systems.
The unique design of NasoNeb specifically treats patients requiring the delivery of medication to the nasal and paranasal sinuses. Until now, patients have only the option of using a standard nebuliser that is designed to delivery medication to other areas of the respiratory system. NasoNeb optimises the effectiveness of your medication and most importantly, ensures medication does not reach other areas of your respiratory system.
NasoNeb nasal nebuliser – why it works …
The patented NasoNeb design combines the correct liquid particle size, airflow and liquid volume to ensure your medication effectively reaches only the nasal and paranasal sinus areas. Two important factors as to why the NasoNeb device should be chosen over other standard nebuliser devices;
1.The unique and specially controlled delivery of patient medication ensures it optimises the treatment of your prescribed medication.
2. The correct particle size and liquid volume combination significantly reduces the risk of the fluid and medication particles reaching other areas of your respiratory system.
NasoNeb nasal nebuliser – clinical references
Two university based outcomes trials demonstrated positive clinical evidence. NasoNeb-delivered budesonide, (Pulmicort Respules® 0.25 mg/2ml), demonstrated statistically-significant objective and subjective outcomes in a peer-reviewed clinical study. 9 NasoNeb-delivered levofloxacin demonstrated a statistically-significant reduction in total bacterial abundance in a peer-reviewed clinical study. 14
NasoNeb-delivered budesonide (Pulmicort Respules®, 0.25 mg/2ml) demonstrated a statistically-significant 50 LPM increase in daily nasal peak inspiratory flow (NPIF) from baseline to endpoint in the treatment arm of a parallel, randomized, double-blinded, placebo controlled clinical trial in a perennial allergic rhinitis patient population.
The authors concluded, in part: “it stands to reason that administering intranasal corticosteroids, which have been shown effective time and again as a treatment for perennial allergic rhinitis, would prove to be even more effective when delivered in this novel way.” Daily nasal peak inspiratory flow on treatment. Median values are depicted. The x-axis shows the study timeline with B = baseline measurement. *p < 0.005 vs baseline for the group on budesonide.
Patients also reported statistically-significant improvements in total nasal symptoms scores (TNSS) and rhinoconjunctivitis quality of life scores.
Daily TNSS on treatment. Median values are depicted. The x-axis shows the study timeline with B = baseline measurement. *p < 0.05 vs respective baselines within treatment groups.